<![CDATA[Antimicrobial resistance is a global health threat, and antibiotic use in hospitals plays a major role in driving resistance. The study aims to evaluate antibiotic use and prescription quality at RSUDZA using data from the 2025 Global Point Prevalence Survey. A prospective cross-sectional survey was conducted using the WHO PPS methodology, involving all inpatients who received antibiotics at the time of the survey. Of the 443 inpatients who met the criteria, 293 (66.1%) received systemic antibiotics, a higher proportion than the national rate (55.9%) and the Southeast Asian rate (46.6%). Antibiotic use was dominated by beta-lactams, particularly third-generation cephalosporins (53.9%). Most therapies were administered for community-acquired infections (85.4%), with a predominance of empirical therapy in CAI and HAI (≥95%), while definitive therapy was very low due to the lack of culture tests (13.3%). Three isolates were identified as resistant organisms. The healthcare-associated infection (HAI) rate was 4.1%, lower than the national and regional comparators, with non-VAP pneumonia as the highest burden. Quality indicators showed that documentation of reasons for antibiotic administration was adequate in medical and surgical wards, but recording of discontinuation dates was low across all units. The use of Watch-list antibiotics dominated, while Access-list antibiotics remained well below the WHO target of ≥60%. These results underscore the need to strengthen the program.]]>
Copyrights © 2026
